Showing 11-20 of 1915 results for "".
- July 2024 - ISSUEShttps://practicaldermatology.com/issues/july-2024/
- January/February 2025 - ISSUEShttps://practicaldermatology.com/issues/january-february-2025/
- May/June 2025 - ISSUEShttps://practicaldermatology.com/issues/may-june-2025/
Papa in at Valeant, J&J Acquires Neostrata, Celebrity Lip Envy
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-papa-in-at-valeant-j-j-acquires-neostrata-celebrity-lip-envy/18772/This edition of DermWireTV brings news that Joseph C. Papa has left Perrigo Company plc, a top five global over-the-counter consumer goods and pharmaceutical company, to take the helm as CEO at Valeant Pharmaceuticals. He will replace J. Micheal Pearson. Valeant also concluded its investigation arouOrtho Dermatologics NDA, J&J Innovation, Consumer Credit Insights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-ortho-dermatologics-nda-j-j-innovation-consumer-credit-insights/18395/Two-thirds of prospective patients say they would be more likely to book a procedure if they were aware of financing options. More than three-quarters of prospective patients are unaware of financing options, according to a recent survey by Zalea. In conjunction with Johnson & Johnson Consumer,To Sell or Not to Sell to Private Equity?
https://practicaldermatology.com/conferences/scale-2023/to-sell-or-not-to-sell-to-private-equity/20195/Joel L. Cohen, MD, and George Hruza MD, discuss the pros and cons of selling to private equity. Pros include back-office support and better pricing on technology and supplies, while cons can include giving up autonomy.Lidocaine Shortage Update
https://practicaldermatology.com/conferences/scale-2023/lidocaine-shortage-update/20196/The current lidocaine and lidocaine with epinephrine shortage is affecting practices across the country. Joel L. Cohen, MD, and George Hruza, MD, weigh in on the shortage and potential solutions and how to minimize toxicity risks when mixing and matching different anesthetics.DermwireTV: Rinvoq Approved for Pediatric Psoriatic Arthritis; J&J Acquires Novel AD Candidate
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rinvoq-approved-for-pediatric-psoriatic-arthritis/26269/In this week's DermwireTV, the FDA approves Rinvoq for pediatric psoriatic arthritis; Johnson & Johnson acquires an AD candidate for $1.25 billion; and the president of Acclaro Medical discusses the latest FDA clearance of its Ultraclear Laser.DermwireTV: J&J Boosts Dermatology Pipeline; New Humira Biosimilar Launched
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-jj-boosts-dermatology-pipeline-new-humira-biosimilar-launched/24561/In this episode of DermwireTV, Johnson & Johnson makes a major acquisition to expand its dermatology treatment pipeline; the first high-concentration, citrate-free biosimilar to Humira is launched in the US; and in the C-Suite Chats feature, the CEO of Benev discusses the medical aesthetic markePhysician Spotlight: George Han, MD, PhD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-george-han-md-phd/23666/